Semaglutide treatment improved liver enzyme levels and cardiometabolic markers in obese individuals, demonstrating hepatic and metabolic benefits during weight loss.
Key findingSemaglutide treatment improved liver enzyme levels and cardiometabolic markers in obese individuals,
What the researchers found
Semaglutide treatment improved liver enzyme levels and cardiometabolic markers in obese individuals, demonstrating hepatic and metabolic benefits during weight loss.
Why it matters
These findings have significant implications for peptide-based therapeutic development and clinical practice.
The numbers in context
Data from December 2020 through November 2024 tracking liver enzymes and cardiometabolic markers in semaglutide-treated patients with obesity and MASH.
How the study worked
Study design and methodology detailed in the full publication.
Who was studied
Adults with obesity and metabolic dysfunction-associated steatohepatitis (MASH) with moderate or advanced fibrosis
What this study cannot tell us
Study-specific limitations discussed in the full publication. Results should be interpreted within the context of study design.
How to read the evidence
Evidence assessment based on study design detailed in publication.
When this study was published
Published in 2025. Current peptide therapeutic research.
The bigger picture
This study contributes to the expanding understanding of how peptide-based therapeutics can be applied across medical specialties.
Questions still open
- What are the long-term implications?
- How do these results compare to existing evidence?
- What further research is needed?
Common questions
What does this study mean for patients?
How reliable are these findings?
Read the original research
Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.
Current medical research and opinion, 41(11), 2089-2102
Citation
Albarmawi, Husam; Dabbous, Firas; Aly, Abdalla; Yousif, Alia; Huse, Samuel; Jara, Maximilian; Quintero, Andres; Lawitz, Eric. (2025). Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.. Current medical research and opinion, 41(11), 2089-2102. https://doi.org/10.1080/03007995.2025.2596430